Trial Profile
A randomized controlled trial of the effects of low dose zoledronic acid on bone density in osteopenic postmenopausal women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2019
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms LoDoZe
- 11 Sep 2017 Results of 3 years open label extension of the core trial published in the CMAJ: Canadian Medical Association Journal
- 09 Nov 2011 Results published in the Journal of Clinical Endocrinology and Metabolism.
- 01 Jul 2009 Additional lead trial centre Health Research Council of New Zealand identified as reported by Australian New Zealand Clinical Trials Registry record.